Biomarkers are an excellent tool for monitoring progressive disease. Seeing biomarkers respond to stem cell-based treatment deepens our excitement about these therapies as potential treatments for MS.”

— Dr. Saud A. Sadiq, founder and director of Tisch MSRCNY

NEW YORK CITY, NY, UNITED STATES, September 18, 2026 /EINPresswire.com/ — Scientists at the Tisch Multiple Sclerosis Research Center of New York (MSRCNY) have identified new biomarkers in multiple sclerosis that may help physicians track the response to stem cell treatment in people with progressive multiple sclerosis, according to a study published today in the journal STEM CELLS Translational Medicine.

Biomarkers are measurable biological indicators, typically found in blood or cerebrospinal fluid (CSF), that reflect changes in disease progression or treatment response. They are valuable diagnostic and treatment tools thanks to their ability to reflect a biological response in a disease before a patient experiences noticeable changes in symptoms.

In this study, researchers analyzed CSF from two groups of individuals with MS before and after treatment with mesenchymal stem cell–derived neural progenitor cells (MSC-NPs). These cells, derived from a patient’s own bone marrow and administered into the CSF, are designed to reduce harmful immune activity and protect nervous system cells.

The researchers identified four biomarkers for MS following treatment:

CCL2 decreased, indicating reduced inflammatory signaling
SCF decreased, reflecting shifts in immune and support cell behavior
MMP9 increased, tied to potential repair processes
CHIT1 increased, linked to potential repair processes

“Biomarkers are an excellent tool for monitoring progressive disease,” says Dr. Saud A. Sadiq, Director of the Center. “In addition to their immediate clinical impact, seeing biomarkers respond to stem cell-based treatment deepens our excitement about the potential of these therapies as a treatment for MS.”

The full study can be accessed here.

About Tisch MS Research Center of New York:
The Tisch MS Research Center of New York is an independent, 501c3 nonprofit research institution dedicated to finding the cause of and cure for multiple sclerosis. Led by award-winning neurologist Dr. Saud Sadiq, the Tisch MSRCNY team conducts industry-leading medical research that rapidly translates from lab bench to bedside. The research center is co-located with the International Multiple Sclerosis Management Practice, a highly rated clinic offering MS patients access to full-service MS management and treatment. Dr. Sadiq’s work is featured in over 150 scientific publications, and he has been named one of America’s Top Doctors by Castle Connolly since 1996.

Jennifer Oliva
Jen Oliva Media
+1 516-584-3361
Jen@Jenolivamedia.com
Visit us on social media:
LinkedIn
Instagram
YouTube

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Media gallery

About The Author
Written By: EIN Presswire